Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H
1988550 citationsG Hale, Herman Waldmann et al.profile →
CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells.
1989547 citationsG Hale, Helen Tighe et al.profile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
This map shows the geographic impact of G Hale's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G Hale with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G Hale more than expected).
This network shows the impact of papers produced by G Hale. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G Hale. The network helps show where G Hale may publish in the future.
Co-authorship network of co-authors of G Hale
This figure shows the co-authorship network connecting the top 25 collaborators of G Hale.
A scholar is included among the top collaborators of G Hale based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with G Hale. G Hale is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Peggs, K, Premini Mahendra, D W Milligan, et al.. (2003). Long term results of reduced intensity transplantation in multiply relapsed and refractory Hodgkin's lymphoma: Evidence of a therapeutically relevant graft-versus-lymphoma effect.. UCL Discovery (University College London).5 indexed citations
5.
Kottaridis, PD, DW Milligan, Charles Craddock, et al.. (2001). Non-myeloablative transplantation for patients with Hodgkin's disease: Limited transplant related mortality and possible evidence of a graft versus Hodgkin's effect.. UCL Discovery (University College London).4 indexed citations
6.
Lundin, Jeanette, Eva Kimby, Magnus Björkholm, et al.. (2001). Phase II study of subcutaneous alemtuzumab (Campath-1H) therapy of patients with previously untreated chronic lymphocytic leukemia (CLL).. Blood. 98.4 indexed citations
7.
Davison, Glenda M., Nicolás Novitzky, Valda Thomas, et al.. (1998). Immune reconstitution following allogeneic bone marrow transplantation depleted of T-cells.. Blood. 92.1 indexed citations
8.
Morgan, Ann W, G Hale, Stephen J. Richards, et al.. (1997). Combination therapy with a TNF antagonist and a CD4 monoclonal antibody in rheumatoid arthritis. A pilot study.. Oxford University Research Archive (ORA) (University of Oxford). 40. 305–305.7 indexed citations
9.
Powles, R, S Meller, CR Pinkerton, et al.. (1996). Autologous transplantation with CD52 monoclonal antibody-purged marrow for acute lymphoblastic leukemia.. British Journal of Haematology. 93. 141–141.1 indexed citations
10.
Treleaven, J, R Powles, S Kulkarni, et al.. (1996). Autografting with CD52 monoclonal antibody-purged marrow for acute lymphoblastic leukemia.. Blood. 88. 1009–1009.2 indexed citations
11.
Steward, Colin G., Peter Goulden, C. Knechtli, et al.. (1996). Unrelated donor bone marrow transplant in childhood ALL. The role of T-cell depletion.. PubMed. 18 Suppl 2. 31–5.6 indexed citations
12.
Lockwood, C M, Simon Stewart, S Thiru, et al.. (1995). HUMANIZED MONOCLONAL-ANTIBODY (MAB) THERAPY FOR WEGENERS GRANULOMATOSIS (WG). Journal of the American Society of Nephrology. 6. 925–925.1 indexed citations
Lim, Seah H., G Hale, Robert Marcus, Herman Waldmann, & Trevor Baglin. (1993). CAMPATH-1 MOAB IN THE TREATMENT OF REFRACTORY AUTOIMMUNE THROMBOCYTOPENIC PURPURA (ATP). British Journal of Haematology. 84. 56–56.2 indexed citations
16.
Naparstek, E, R. Or, Arnon Nagler, et al.. (1993). ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR LEUKEMIA USING CAMPATH-1 MONOCLONAL-ANTIBODIES AND POSTTRANSPLANT ALLOIMMUNIZATION WITH DONOR LYMPHOCYTES. Experimental Hematology. 21. 1061–1061.3 indexed citations
17.
Isaacs, John D., Richard A. Watts, B L Hazleman, G Hale, & Herman Waldmann. (1992). HUMANIZED MONOCLONAL-ANTIBODY THERAPY IN RHEUMATOID-ARTHRITIS. Oxford University Research Archive (ORA) (University of Oxford). 35.7 indexed citations
Waldmann, Herman, et al.. (1985). RAT MONOCLONAL-ANTIBODIES FOR BONE-MARROW TRANSPLANTATION (BMT) - THE CAMPATH SERIES. Experimental Hematology. 13. 431–431.2 indexed citations
20.
Slavin, Shimon, Herman Waldmann, Reuven Or, et al.. (1985). PREVENTION OF GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR LEUKEMIA BY T-CELL DEPLETION INVITRO PRIOR TO TRANSPLANTATION. Transplantation Proceedings. 17. 465–467.21 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.